Ocrelizumab for Schizoaffective Disorder (OPA Trial)

"Indeed, the details available on clinicaltrials.gov affirm that this research is actively pursuing eligible participants. The study was initially listed on October 1st, 2019 and last revised on February 6th, 2024. Recruitment aims to enroll a total of 40 individuals at a single investigational site."

"Affirmative. Records from clinicaltrials.gov indicate that this investigation is actively seeking volunteers. This study was initially disclosed on October 1st, 2019 and underwent its latest revision on February 6th, 2024. The trial aims to enroll a total of 40 participants across one designated location."

"This clinical research endeavor aims to recruit 40 individuals diagnosed with schizoaffective disorder aged between 18 and 35. Essential inclusion criteria include: Being of either gender within the specified age range, Presenting an active psychotic condition aligning with DSM-5 standards for Schizophrenia Spectrum Disorder as per the Mini International Neuropsychiatric Interview (MINI), Demonstrating a total PANSS score of ≥60 along with a minimum score of ≥4 on at least two PANSS positive symptoms, Displaying normal academic achievements until reaching the age of 15 without any psychiatric manifestations before that period, Possessing the capacity to provide informed ass"

"Eligibility requirements for this study dictate that participants must be between 18 and 35 years old. Notably, there are a total of 140 trials catering to individuals under the age of 18 and 385 studies focusing on patients above the age of 65."

"At present, there are 5 ongoing clinical investigations exploring Ocrelizumab. Among these, 2 trials are in the advanced Phase 3 stage. While a significant number of research endeavors on Ocrelizumab are centered in Cincinnati, Ohio, there is an extensive network of 303 sites globally conducting studies with this therapeutic agent."

"Currently, there are 5 ongoing investigations on Ocrelizumab being conducted in a vast network of 115 urban areas spanning across 28 nations. The initial clinical exploration involving this drug commenced in the year 2018 under the sponsorship of Roche Pharma AG. In its Phase III progression for regulatory endorsement, this investigation successfully engaged 51 individuals. Subsequently, after its initiation in 2018, a total of seven research initiatives have reached completion status."